– NETHERLANDS, Amsterdam – uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors.
Rachelle Jacques has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial, and has led successful launches of several rare disease therapies including the recent approval of a Regenerative Medicine Advanced Therapy-designated product, one of only three since the program inception in 2016.
“It is with great pleasure that we welcome Rachelle to the uniQure board,” said CEO, Matthew Kapusta. “Her considerable biotechnology experience, including her work in the rare disease space across many functional areas, will be a valuable asset for uniQure as we work to advance our pipeline candidates.”
Rachelle Jacques will also join the Audit Committee.
About Rachelle Jacques
Since February 2019, Ms. Jacques has served as the CEO of Enzyvant Therapeutics Inc, focusing on the development of transformative regenerative therapies for rare diseases. From August 2017 to February 2019, she served as the SVP and Global Complement Franchise Head at Alexion Pharmaceuticals, Inc., where she was responsible for global franchise strategy development and execution across the therapeutic areas of hematology, nephrology, and neurology. From January 2016 to June 2017, she was VP of U.S. Hematology Marketing at Baxalta Inc. and then Shire plc, following Shire’s acquisition of Baxalta in 2016. From July 2015 to June 2016, she served as VP of Business Operations at Baxalta Inc. after its spinoff from Baxter International Inc. Ms. Jacques held multiple leadership positions at Baxter, including VP of Finance, U.S. BioScience Business. Earlier in her career, Ms. Jacques served in various roles at Dow Corning Corporation, including operational management positions in the U.S., Europe, and China.
“I am pleased with this opportunity to join the uniQure Board of Directors at such an exciting time for the Company,” commented Rachelle Jacques. “I look forward to partnering with Board members and providing consult to management as it prepares to submit a BLA in hemophilia B, advances its Huntington’s disease clinical program, and develops its pipeline of promising gene therapy candidates.”
Ms. Jacques received her B.A. degree in business administration from Alma College. She has also served as a financial auditor for Ernst & Young and Deloitte and Touche. Since April 2019, Ms. Jacques has served on the Board of Directors of Corbus Pharmaceuticals (NASDAQ: CRBP), and from April 2020 to February 2021, she served on the Board of Directors of Viela Bio. She is co-chair of the Alliance for Regenerative Medicine Tissue Engineering & Biomaterials Committee and is a founding member of the ARM Action for Equality Task Force.
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system and liver, including clinical programs in hemophilia B and Huntington’s disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimer’s, Parkinson’s, and ALS.
For more information: http://uniqure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.